Eli Lilly & Co. is pouring $4.5 billion into a new manufacturing plant in Indiana to make drugs for future clinical trials, part of a broader push to shore up the company’s supply chain.

Oct 2 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab said on Wednesday it will invest $4.5 billion to create a new center in Indiana that will focus on developing new ways to ...

Earnings Report 1.453 USD Q3 2024 Earnings Release 10/30/2024 Earnings Report 5.438 USD Q4 2024 Earnings Release 01/30/2025 Earnings Report 5.271 USD Q1 2025 Earnings Release 04/24/2025 Earnings ...

Eli Lilly and Company (NYSE: LLY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for ...

Ruth McCully, age 88, of Ames, passed away October 11 ... and Tim Burianek; Great-grandchildren: Lily Martin and Ember Burianek; and sisters Joyce Coleman and Jackie Edmonson. In lieu of flowers, ...

Oct 2 (Reuters) - The U.S. Food and Drug Administration removed Eli Lilly's (LLY.N), opens new tab blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely ...

Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Eli Lilly’s two weight loss drugs have become blockbusters, bringing in more than $1 billion in annual revenue. Demand is growing in this market, but so is competition. These players ...

WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of a world in constant transformation. The WIRED conversation illuminates how technology is ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to ...

Eli Lilly Says Ebglyss Improves Atopic Dermatitis Symptoms in New Phase 3B Data New results show Eli Lilly and Company's (NYSE: LLY) EBGLYSS improved skin (including hand and face) and itch among ...